Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing: earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures gives cross-border investors faster access to Tokyo-listed disclosures.
This corporate disclosure from J-Pharma Co.,Ltd. was processed by Pulse News Wire on May 14, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO, May 14 (Pulse News Wire) – J-Pharma Co., Ltd. (520A.T) reported non-consolidated results for fiscal year 2026 ending March. Revenue was ¥4.8 billion. operating profit was ¥4,378 million (+85.4%
View all J-Pharma Co.,Ltd. disclosures →
TOKYO, May 14 (Pulse News Wire) – J-Pharma Co., Ltd. (520A.T) reported non-consolidated results for fiscal year 2026 ending March.
Revenue was ¥4.8 billion. operating profit was ¥4,378 million (+85.4%).
Total assets stood at ¥4.8 billion with an equity ratio of 85.4%.
🟢 Confidence: High AI-translated content.